Sepiwhite MSH Powder

Undecylenoyl phenylalanine, the active ingredient associated with Sepiwhite MSH, is studied for its effects on α-melanocyte-stimulating hormone (α-MSH)–related pigmentation signaling.

α-MSH participates in melanogenesis through the melanocortin 1 receptor (MC1R). The downstream signaling network involves cAMP, protein kinase A, CREB, MITF, and pigmentation-related proteins such as tyrosinase.

A useful research framework is:

α-MSH stimulation → receptor-associated signaling → changes in melanogenic gene and protein expression → altered melanin production.

Tyrosinase-related research should distinguish three possibilities:

• Direct inhibition of enzyme catalytic activity.
• Reduced expression or maturation of cellular tyrosinase.
• Lower total melanin resulting from reduced cell number or viability.

An original formulation study evaluated undecylenoyl phenylalanine using both mushroom tyrosinase and cellular tyrosinase assays. These findings provide evidence under the tested conditions, but do not establish that direct enzyme inhibition explains all effects observed in human skin.

Published controlled human studies provide evidence for selected formulations containing undecylenoyl phenylalanine. Their results should remain linked to the tested formulation, population, and observation period.

• Facial Hyperpigmentation and Niacinamide Combinations

Two randomized, double-blind, split-face studies published in 2009 evaluated formulations including vehicle, 5% niacinamide, and 5% niacinamide plus 1% undecylenoyl phenylalanine.

After eight weeks of application, the combination formulation reduced the appearance of facial hyperpigmentation more effectively than vehicle or 5% niacinamide alone.

• Other Pigmentation Studies

A 12-week melasma study enrolled 40 women, of whom 37 completed the study. Among the 20 participants assigned to the formulation containing 2% undecylenoyl phenylalanine, 17 showed partial improvement; none showed complete clearance.

A separate 12-week study of solar lentigines on the hands had 30 completers and reported greater improvement on the active-formulation side than on the vehicle side. Minor reactions included redness, itching, or burning.

Undecylenoyl phenylalanine has been investigated in nanostructured lipid carriers (NLCs), with measurements covering particle size, encapsulation efficiency, release, and ex vivo skin distribution.

Under the study conditions, its release and skin-accumulation profiles differed from those of a conventional emulsion.

These results illustrate why formulations containing the same nominal concentration can produce different tissue-exposure profiles. However, ex vivo findings cannot substitute for human efficacy testing or demonstrate that every nanocarrier is superior.

Delivery studies should distinguish:

Surface residue → stratum corneum retention → epidermal deposition → dermal distribution → appearance in receptor fluid.

A complete mass balance and blank-carrier controls help determine whether observed differences arise from the active ingredient, the carrier, or changes in barrier integrity.

Small controlled human studies provide some information on local tolerability, while also documenting irritation-related reactions. Undecylenoyl phenylalanine should therefore not be described as universally non-irritating, and short-term findings cannot establish safety for every population, exposure pattern, or formulation.

From a research perspective, Sepiwhite MSH connects pigmentation-signaling studies, skin-delivery development, and finished-product appearance assessments.